Updated recommendations for cholesterol management now suggest a broader approach to preventing cardiovascular disease, including a one-time blood test for lipoprotein(a), a genetic marker linked to heart attacks and strokes, reports Baltimore Chronicle. These guidelines, released jointly by the American Heart Association (AHA) and the American College of Cardiology (ACC) on Friday, emphasize earlier detection and treatment to reduce heart disease, which remains the leading cause of death among both men and women in the United States.
Dr. Roger Blumenthal, a cardiologist at Johns Hopkins in Baltimore and chair of the guideline committee, highlighted that more than 80% of cardiovascular events are preventable and that elevated low-density lipoprotein (LDL), often referred to as “bad” cholesterol, contributes significantly to this risk. He noted that assessing LDL alone may not provide a complete understanding of an individual’s risk and that measuring additional biomarkers, including lipoprotein(a), offers a more comprehensive evaluation.
Lipoprotein(a) testing is straightforward and increasingly available in primary care settings. Because its levels are largely determined by genetics and remain stable over a person’s lifetime, the test generally only needs to be conducted once, ideally in early adulthood. High lipoprotein(a) levels indicate an inherited predisposition to cardiovascular complications, including heart attacks and strokes.
The updated recommendations also encourage wider use of coronary calcium scoring, a noninvasive imaging technique that quantifies calcified plaque in the arteries. Clinicians are advised to incorporate risk prediction tools such as PREVENT, which estimates 10-year and 30-year cardiovascular risk to guide decisions about initiating lipid-lowering therapy.
Statins remain the primary pharmaceutical option for reducing high cholesterol. Under the new guidelines, even individuals with moderate or relatively low short-term risk may be considered for early treatment if their overall lifetime risk is elevated. Dr. Steven Nissen, a preventive cardiologist at Cleveland Clinic, described this as a fundamental shift, emphasizing that a patient’s cumulative risk over a lifetime is a critical factor in treatment decisions.
The guidelines predict a significant increase in the number of adults receiving cholesterol-lowering therapy. Generic statins are affordable, with some costing as little as $3 per month, making earlier intervention feasible on a large scale. Approximately 25% of American adults have high LDL levels, putting them at greater risk of cardiovascular events.
Beyond medications, the guidelines underline the importance of lifestyle modifications. Regular exercise, abstaining from tobacco, and maintaining adequate sleep are integral components of cardiac prevention. Leslie Cho, also a preventive cardiologist at Cleveland Clinic, stressed that diet and physical activity remain the foundation of heart health.
These recommendations are documented in the journals Circulation and JACC, the Journal of the American College of Cardiology, and aim to provide clinicians with more precise tools to manage cardiovascular risk effectively.
Earlier we wrote that FBI Warns of Iran Drone Threats to California Amid U.S.-Iran Conflict
